1. Cutaneous adverse reactions resulting from targeted cancer therapies: histopathologic and clinical findings
   Dylan Haynes et al, 2023, Human Pathology CrossRef
2. Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis
   Seung-Hyeon Cha et al, 2023, Acta Oncologica CrossRef
3. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis
   Brian M. Wei et al, 2024, Journal of the American Academy of Dermatology CrossRef
4. Dermatological adverse drug reactions to tyrosine kinase inhibitors: a narrative review
   Anupam Das et al, 2023, Clinical and Experimental Dermatology CrossRef
5. Evaluation of Delayed-Type Hypersensitivity to Antineoplastic Drugs—An Overview
   Inés Roger et al, 2023, Cancers CrossRef
6. Successful Desensitization to Sorafenib and Imatinib—A Report of Two Cases and a Literature Review
   Natasa Kusic et al, 2024, Healthcare CrossRef
7. Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer
   James Chih-Hsin Yang et al, 2023, Expert Review of Anticancer Therapy CrossRef